
Opinion|Videos|May 14, 2024
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
5



























